ArticleClinical hematology international2026
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.
Article in Clinical hematology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is an incurable hematological malignancy with increasing prevalence. While randomized controlled trials have demonstrated survival improvements, they underrepresent older and comorbid patients. Real-world data from observational cohorts are therefore essential. Objective: To assess the comparability of patient, hospitalization and center characteristics for patients treated in centers included in the French Epidemiology of Multiple MYeloma (EmmY) cohort with those treated in centers of the French-speaking Intergroupe Francophone du Myélome (IFM) network (including EmmY) and those treated in all centers treating MM in France between 2017-2023. Methods: We analyzed French national hospital discharge data (PMSI) to identify adults hospitalized with MM (ICD-10 C90) between August 2017 and December 2023. Patient demographics, comorbidities, hospitalization characteristics, and center profiles were compared between the three cohorts using standardized differences. Results: We identified 69,276 patients (including 50,243 IFM and 33,785 EmmY), 1,871,369 hospitalizations (including 1,484,288 IFM and 1,022,462 EmmY), and 323 centers (including 118 IFM and 70 EmmY). EmmY centers were larger and treated a higher mean proportion of MM patients (2.7%) per center than IFM (2.4%) and all MM centers (1.3%). No clinically meaningful differences were observed between EmmY and IFM centers regarding patient age, sex, comorbidities, treatment patterns, or hospitalization outcomes. Conclusions: The EmmY cohort is highly comparable to patients treated in specialized MM centers and those within the broader French MM population, supporting its validity as a robust real-world data source. It is well-suited for evaluating treatment pathways and outcomes in real-world MM populations, including patients underrepresented in randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.